Alphyn Biologics

Alphyn Biologics is a private, clinical-stage biotech focused on transformative dermatology treatments. The company leverages its proprietary Zabalafin Platform to develop Multi-Target Therapeutics (MTT) that simultaneously address inflammation, infection, and itch in skin diseases. Its lead program, zabalafin hydrogel, has shown positive Phase 2a results in atopic dermatitis and is now in a global Phase 2b trial, with a second program for molluscum contagiosum also in Phase 2. Founded in 2016 and headquartered in Boston, Alphyn aims to become a leader in dermatology by addressing unmet needs for safe, long-term therapies.

Zabalafin Platform (AB-101 Platform) for developing Multi-Target Therapeutics (MTT) containing multiple bioactive compounds to attack diseases through multiple mechanisms simultaneously.

Alphyn competes in a crowded atopic dermatitis market against topical steroids, calcineurin inhibitors, PDE4 inhibitors (e.g., crisaborole), and newer systemic therapies. Its differentiation hinges on being a steroid-free topical that simultaneously treats inflammation and infection, a combination not offered by current leading topicals.